

Autoantibodies in Lung Cancer – possibilities for early detection and subsequent cure.

Supplementary data

Autoantibody panel 1/7 sensitivity in lung cancer by age

Number and percentage positivity (% +ve) with 95 % confidence interval (95% CI) in each patient group using Panel1/7. All LC: all lung cancer samples tested.

Age group		All LC
36-50	number +ve	9/15
	% +ve (95% CI)	60 (32,84)
50-59	number +ve	20/23
	% +ve (95% CI)	87 (66,97)
60-69	number +ve	24/33
	% +ve (95% CI)	73 (54,87)
70-82	number +ve	26/33
	% +ve (95% CI)	79 (61,91)
All LC		
number +ve		79/104
% +ve (95% CI)		76 (67,84)

Autoantibody panel 1/7 sensitivity in lung cancer by gender

Number and percentage positivity (% +ve) with 95 % confidence interval (95% CI) in each patient group using Panel1/7. All LC: all lung cancer samples where information on gender was available.

Group		All LC
male	number +ve	59/72
	% +ve (95% CI)	82 (71, 90)
female	number +ve	20/31
	% +ve (95% CI)	65 (45, 81)

Frequency of autoantibodies to CAGE and GBU 4-5 in breast cancer

Number and percentage positivity (% +ve) with 95 % confidence interval (95% CI) in each patient group. Positivity was defined as a value greater than the mean of the normal population plus 2SD. PBC: Primary invasive breast cancer sera.

Normal: matched female sera from individuals discharged as normal following mammographic screening.

(Sample details in Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in Breast Cancer: their use as an aid to early diagnosis. *Annals of Oncology* 18: 868-73, 2007)

Group			Number and percentage positive	
Total			CAGE	GBU 4-5
PBC	n	51	3	3
	%+ve (95% CI)		6 (1, 16)	4 (0, 13)
Normal	n	31	1	2
	%+ve (95% CI)		3 (0, 17)	6 (1, 21)